Appropriately, a recent study has shown that antibody-mediated TGF-β blockade using the TGFβ-neutralising mAb 1D11 can efficiently enhance radiation-induced cancer treatment through enhancing cytotoxic CD8+ T cell responses in a mouse breast cancer model [177]. Here, TGFB1 is linked to breast cancer.